<?xml version="1.0" encoding="UTF-8"?>
<p>We noted a recently planned open-label, randomised controlled trial of rhACE2 for treatment of patients with COVID-19 in Wuhan.
 <xref rid="R41" ref-type="bibr">41</xref> Further studies will be required to identify whether ACE2 therapy should be targeted only at high-risk cardiovascular patients or all patients at risk of progression to cardiorespiratory failure and death.
</p>
